Brainomix, Boehringer Ingelheim Advance Partnership in Pulmonary Fibrosis

Brainomix is expanding its partnership with Boehringer Ingelheim to improve progressive pulmonary fibrosis (PPF) patient care.

Patients with Interstitial Lung Diseases (ILD) may progress to PPF, a condition marked by irreversible lung damage and increased risk of early mortality. Without treatment, patients may have a lifespan as short as five years,¹ yet many still endure long delays—often years—before receiving a diagnosis.² Early diagnosis and intervention can play a major role in a patient’s prognosis, but determining patient eligibility for treatment based on imaging remains challenging, even for experienced specialists.

“We are excited to expand our strategic partnership with Boehringer Ingelheim, a leader and innovator in this field, with whom we share a firm commitment to improving outcomes for people living with pulmonary fibrosis,” Brainomix Co-Founder/CEO Dr. Michalis Papadakis said. “The evidence generated to date for e-Lung is highly compelling, showing the technology has the potential to accelerate diagnosis by more than two years. This next phase will enable us to evaluate that potential at scale, providing robust real-world validation of what we expect could be a transformative advancement in the patient care pathway.”

Brainomix e-Lung is a U.S. Food and Drug Administration-cleared, artificial intelligence (AI)-driven imaging software platform that automatically detects and quantifies abnormalities on thoracic CT scans, helping clinicians more easily identify changes, including subtle deterioration across multiple timepoints. Built on proprietary technology, e-Lung has been clinically validated to measure lung features associated with ILD.

Results from REVISE-PPF, a retrospective research study conducted with the University of Chicago, Weill Cornell Medical Center, and the University of Alabama at Birmingham, will be presented by Dr. Anna Podolanczuk (Weill-Cornell) at an ATS session on May 17. The study demonstrated that e-Lung could stratify patients at risk of PPF from a baseline CT and identify patients with radiologic PPF evidence up to 28 months before local clinical diagnoses.

This next phase of the Brainomix–Boehringer Ingelheim partnership aims to advance the work further, centered around a prospective, mixed-methods study, PROGRESS-PPF. Conducted across multiple U.S. sites, it will generate both quantitative and qualitative real-world evidence to evaluate whether the routine use of e-Lung can support earlier PPF clinical diagnosis, enabling treatment to begin sooner in the disease course, and, ultimately, support improved patient outcomes.

“Boehringer Ingelheim is proud to expand our partnership with Brainomix as part of our continued commitment to improving care for people living with pulmonary fibrosis,” said Dr. Emmanuelle Clerisme-Beaty, senior vice president of Medicine & Regulatory Affairs at Boehringer Ingelheim. “Progressive pulmonary fibrosis can be challenging to diagnose, and innovations that enhance our ability to detect disease have the potential to improve patient outcomes.”

Brainomix is a global pioneer in AI medical imaging, enabling precision medicine for better treatment decisions in stroke and lung fibrosis. Its flagship product, Brainomix 360 Stroke, is reportedly the world’s first fully automated AI-imaging platform, designed for acute stroke assessment at all points of the patient pathway, facilitating more confident treatment and transfer decisions for patients in all hospitals, regardless of local resources or expertise. Brainomix 360 e-Lung technology applies AI-driven CT biomarkers to identify, monitor, and predict disease progression in pulmonary fibrosis. Founded as a spinout from the University of Oxford, Brainomix has offices in the United Kingdom, Ireland , and the United States, and operations in more than 20 countries.

References
¹ Khor YH et al. Patient characteristics and survival for progressive pulmonary fibrosis using different definitions. Am J Respir Crit Care Med. 2023 Jan.
² Rajan SK et al. Progressive pulmonary fibrosis: an expert group consensus statement. Eur Respir J. 2023 Mar.